Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib in Combination Therapies for Advanced Solid Malignancies
NCT02264678Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of ceralasertib in solid tumor, gastric adenocarcinoma, breast cancer and 3 more (14 arms), sponsored by AstraZeneca. Primary endpoints: Number of subjects with adverse events/serious adverse events, Effect of food on ceralasertib absorption by Intensive PK assessments and 1 more. Started Oct 2014; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
solid tumorgastric adenocarcinomabreast cancerovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02264678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264678.